RAPT Therapeutics (RAPT) Invested Capital (2020 - 2024)
Historic Invested Capital for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $95.5 million.
- Therapeutics' Invested Capital fell 4473.03% to $95.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $95.5 million, marking a year-over-year decrease of 4473.03%. This contributed to the annual value of $147.0 million for FY2023, which is 4002.63% down from last year.
- Therapeutics' Invested Capital amounted to $95.5 million in Q3 2024, which was down 4473.03% from $109.2 million recorded in Q2 2024.
- Therapeutics' 5-year Invested Capital high stood at $245.2 million for Q4 2022, and its period low was $91.6 million during Q1 2021.
- Moreover, its 5-year median value for Invested Capital was $167.8 million (2022), whereas its average is $160.3 million.
- As far as peak fluctuations go, Therapeutics' Invested Capital surged by 8344.25% in 2021, and later tumbled by 4530.17% in 2024.
- Over the past 5 years, Therapeutics' Invested Capital (Quarter) stood at $104.2 million in 2020, then surged by 78.9% to $186.4 million in 2021, then surged by 31.54% to $245.2 million in 2022, then crashed by 40.03% to $147.0 million in 2023, then plummeted by 35.05% to $95.5 million in 2024.
- Its last three reported values are $95.5 million in Q3 2024, $109.2 million for Q2 2024, and $130.8 million during Q1 2024.